Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $18.75 Average Price Target from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO) have been assigned an average recommendation of “Buy” from the nine research firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $18.75.

LXEO has been the subject of several research reports. JPMorgan Chase & Co. reduced their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating for the company in a research report on Thursday, June 25th. Weiss Ratings cut shares of Lexeo Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 30th. Wall Street Zen cut Lexeo Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday. Finally, Chardan Capital raised Lexeo Therapeutics to a “strong-buy” rating in a research report on Tuesday, July 28th.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock opened at $4.84 on Monday. The stock has a market capitalization of $380.05 million, a PE ratio of -4.21 and a beta of 1.46. The company has a 50-day simple moving average of $4.65 and a two-hundred day simple moving average of $5.63. Lexeo Therapeutics has a 52-week low of $3.99 and a 52-week high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last issued its earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). As a group, equities research analysts forecast that Lexeo Therapeutics will post -1.2 EPS for the current fiscal year.

Insider Buying and Selling at Lexeo Therapeutics

In other news, insider Narinder Pal Bhalla sold 22,306 shares of the firm’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the transaction, the insider directly owned 82,194 shares in the company, valued at approximately $363,297.48. This trade represents a 21.35% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total value of $116,242.56. Following the sale, the chief executive officer owned 377,817 shares of the company’s stock, valued at $1,692,620.16. This trade represents a 6.43% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last quarter, insiders have sold 62,204 shares of company stock worth $280,089. Insiders own 2.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Dimensional Fund Advisors LP increased its holdings in Lexeo Therapeutics by 27.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 1,103,584 shares of the company’s stock valued at $6,332,000 after acquiring an additional 240,692 shares in the last quarter. Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Lexeo Therapeutics in the second quarter valued at approximately $1,237,000. Spruce Street Capital LP grew its position in shares of Lexeo Therapeutics by 430.6% in the first quarter. Spruce Street Capital LP now owns 928,593 shares of the company’s stock valued at $5,330,000 after purchasing an additional 753,593 shares during the last quarter. Affinity Asset Advisors LLC increased its stake in shares of Lexeo Therapeutics by 57.8% during the 1st quarter. Affinity Asset Advisors LLC now owns 5,050,211 shares of the company’s stock worth $28,988,000 after purchasing an additional 1,850,211 shares in the last quarter. Finally, Orbimed Advisors LLC raised its position in shares of Lexeo Therapeutics by 69.5% during the 1st quarter. Orbimed Advisors LLC now owns 3,602,450 shares of the company’s stock worth $20,678,000 after purchasing an additional 1,477,450 shares during the last quarter. Hedge funds and other institutional investors own 60.67% of the company’s stock.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.